iJRASET

International Journal For Research in
Applied Science and Engineering Technology

INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY

Volume: 6 Issue: III Month of publication: March 2018

DOI: <http://doi.org/10.22214/ijraset.2018.3198>

www.ijraset.com

Call: ☎ 08813907089

E-mail ID: ijraset@gmail.com

Actinomycetes: A General Review

Rinkal Chauhan¹, Srivathsa Nallanchakravarthula²

¹ C. G. Bhakta Institute of Biotechnology, Uka Tarsadia University,

² Gopal vidya nagar, Tarsadi, Bardoli-Mahuva road, Surat (dist), Gujarat, India

Abstract: Actinomycetes are the most prolific group of microorganisms. They are wide in distribution and known to occur in various environments. They produce various metabolites that are of industrial importance and therapeutic importance. These metabolites are known to control many human and plant pathogens. A huge number of currently used antibiotics including erythromycin, streptomycin, rifamycin and gentamycin, are isolated from soil and marine actinomycetes. This review summarizes about the actinomycetes from soil and marine environments including structure, taxonomy, pigmentation, advantages and disadvantages.

Keywords: Actinomycetes, harmful, beneficial, pigment, antibiotics

I. INTRODUCTION

The word ‘Actinomycetes’ stands for “atkis” (a ray) and “mykes” (fungus) in Greek [1]. Actinomycetes are the group of microorganisms that exhibit the characteristics of both bacteria and fungi. They were considered as an intermediate group in between bacteria and fungi but latter on they were separated as a different group [2]. They are known to form thread-like filaments in soil, grow like fungal hyphae and are gram positive bacteria with high G+C content. They are present in terrestrial and aquatic systems [1]-[4]. Various metabolites that are economically valuable, such as antibiotics, anti-tumor agents immunosuppressive agents and enzymes are known to be produced by these organisms [3], [4]. They are also responsible for the characteristic ‘earth’ smell which is being attributed to Geosmin, a metabolite [5], [6]. Taxonomically, actinomycetes belongs class Actinobacteria of phylum Firmicutes. They are further divided into eight families such as Actinoplanaceae, Actinomycetaceae, Dermatophilaceae, Frankiaceae, Micromonosporaceae, Mycobacteriaceae, Nocardiaceae and Streptomycetaceae and has more than sixty genera [7]. Some of the representative genera of actinomycetes are Streptomyces, Actinomyces, Arthrobacter, Corynebacterium, Frankia, Micrococcus, Micromonospora and several others.

Cell wall of actinomycetes is known to be very rigid and maintains its structure. Sometimes in high osmotic pressure conditions the cell burst is prevented [8], [9]. Their cell wall consists of peptidoglycan, teichoic and teichuronic acid and polysaccharides [8] [10]. The cell wall composition is similar to gram positive bacteria due to its well-developed morphological and cultural charactersitics [1], [11] (Das et al., 2008; Cummins and Harris, 1954)^{1, 11}. They exhibit mycelial growth and produce spores. Based on their cell wall constituents the actinomycetes were classified into four different groups [12].

TABLE 1. CELL WALL TYPES IN ACTINOMYCETES

S.no	Cell wall type	Sugar Pattern	Genera examples
1	I	No characteristic sugar pattern	Streptomyces, Streptovercillium
2	II	Araginose, Xylose (monosaccharide)	Actinoplanes, Micromonospora
3	III	No Sugar	Dermatophilus, Planomonospora
4	IV	Galactose, Arabinose	Mycobacterium, Nocardia

(Adapted from Lechevalier and Lechevalier, 1970)¹².

Diverse physiological and metabolic properties are exhibited by actinomycetes [13], [14]. Various secondary metabolites from actinomycetes has been reviewed by [15]. The secondary metabolites that are produced by this group are known to have various biological activities especially those that are antagonistic in function [16]-[21]. Streptomyces genera members are known to produce more than 10,000 metabolites including volatile organic compounds [22]-[24]. Not only metabolites of clinical significance but also of industrial importance are being produced by these organisms such as colour pigments. Natural colours are produced by plants, animals and various groups of microorganisms including actinomycetes. These natural colour pigments are being used for different purposes (for eg. colouring agents, antioxidants and etc) in food and pharmaceutical industries [25].

TABLE 2. PIGMENTS PRODUCED BY ACTINOMYCETES MEMBERS

S.no	Pigment	Organism	Study
1	Anthracyclin glycoside	Streptomyces galilaeus, Streptomyces melanogenes, Streptomyces peucetius	Cassinelli et al 1982 [26]
2	Carotenoids	Streptomyces griseus, Streptomyces setonii, Streptomyces coelicolor	Takano et al 2006 [27]
3	Melanin	Streptomyces	Conn and Conn 1943 [28]
4	Naphthoquinone	Streptomyces coelicolor	Gerber and Wiclawek 1966 [29]
5	Prodigiosin	Serratia, S treptovercillium rubireticuli, Streptomyces longisporus	Venil and Lakshmanaperumalsamy 2009 [30]
6	Phenoxazinone	Streptomyces parvullus	Smith et al 2004 [31]
7	Violacein	Chromobacterium violaceum	Justo et al 2007 [32]

Studies have also shown that pigments isolated from actinomycetes members were shown antibacterial activities and industrial importance [33]-[35].

A. Actinomycetes From Soil Environment

Traditionally soil has been the source for the isolation of medicinally important actinomycetes. Nearly 80% of the commercially available secondary metabolites are from soil actinomycetes [36]. Of these, actinomycetales is an important group [17]. This order has nearly 80 genera that are mostly terrestrial in origin, some of them are aquatic and plant colonizers showing a diverse chemical and morphological characteristics, but also shows a distinct evolutionary line [37]. Primarily these are soil microorganisms that were found to have wide distribution ranging from deep sea soil sediments, low temperatures, soil from Antarctica and desert soil [38]-[44]. Many secondary metabolites are produced in different capacities that are known to have high commercial value, for which they are regularly screened for new metabolites [45], [46]. Antibiotics such as erythromycin, streptomycin, rifamycin, gentamycin and many others that are currently used are from soil actinomycetes [47]. Streptomyces and Micromonospora are the two major groups from which most of the antibiotics are isolated. Streptomyces accounts for nearly 80% of the antibiotics that are in use followed by Micromonospora with about one tenth of Streptomyces [48]. Streptomyces species is mostly being exploited by the industry for therapeutically important metabolites [22]. Streptomyces are known to be spore formers and shows filamentous nature [49], [50]. Members of this genera are shown to be devoid of any diagnostic sugar followed by a LL isomer of '2, 6- Diaminopimelic acid (LL-DAP)' [51].

B. Actinomycetes from Marine Environment

Nearly ¾ th of the earth consists of sea water which hosts remarkable biodiversity [52]. Less than 10% of the sea surface is coastal area and the remaining is deep sea, more than 50% of it is more than 2000 m depth [52]. The deep sea environments are characterized by low light or completely lacks light, salinity, high pressures, low temperatures and less oxygen concentrations [53]. In spite of being geographically vast, information about the deep sea microbial diversity is scanty [52]. However, this environment was shown to be a source of novel organisms that are of therapeutic value and are less explored [53]. Due to the increasing number of aggressive pathogens, therapeutically important metabolites from actinomycetes especially from the marine environments may have an answer to combat these pathogens [54], [55]. Marine actinomycetes were shown to produce novel secondary metabolites [54], [55]. In 1984, it was a marine actinomycete Rhodococcus marinonascene that was first characterized [56]. After which, many studies were performed on the marine actinomycetes, some of them showed metabolic activities and some displayed adaptations to marine environment [57], [58]. The diversity of marine actinomycetes and their bioactive potential has been comprehensively reviewed by [59]. Most of the isolates belonged to Actinomadura, Aeromicrobium, Dietzia, Gordonia, Marinophilus, Micromonospora, Nonomurea, Rhodococcus, Saccharomonospora, Saccharopolyspora, Salinispora, Streptomyces, Solwaraspora, Williamsia, Verrucosipora and several others genera. Streptomyces is also known to be present in marine systems and is known to be one of the largest number of species that shows diversity in physiology, morphology and their biochemical properties [59]. Salinispora genera was the first obligate marine actinomycete that was discovered [60]. Its members Salinispora arenicola and Salinispora tropica were also discovered to be obligate in nature [61].

Numerous pharmaceutically important metabolites have been isolated from marine actinomycetes, such as Abyssomicin C and Diazepinomicin [62] [63] (Riegdlinger et al 2004; Charan et al 2004) ^{62, 63}. Lam 2005 [54] has also reviewed actinomycetes metabolites from marine environments. Compounds such as Abyssomicins, Aureovorticillactam, Bonactin, Caprolactones, Chandrananimycins, Chinikomycins, Chlorodihydroquinones, Diazepinomicin, 3,6-disubstituted indoles, Frigocyclinone, Glaciapyrroles, Gutingimycin, Helquinoline, Himalomycins, Komodoquinone A, Lajollamycin, Marinomycins, Mechercharmucins, Salinosporamide A, Sporolides, Trioxacarcins and others that are known to have antimicrobial properties were majorly isolated from marine isolates of *Streptomyces* and *Salinispora* genera [54]. Many different classes of antibiotics such as pyridinium, chlorinated dihydroquinones and cyclomarazines were reported to be produced by *Amycolatopsis alba* var. nov. DVR D4, *Streptomyces* strain CNQ-525 and *Salinispora arenicola* [64]-[66]. Cyclomarazines that were isolated from *Salinispora arenicola* showed inhibition against Vancomycin Resistant Enterococci (VRE) and Methicillin Resistant *Staphylococcus aureus* (MRSA) [64]. Nearly 70% of the *Streptomyces* members that were isolated from marine mollusks showed antagonistic properties but whereas only 20-25% of the same sediment isolates showed antagonism to the test organism [67]. Metabolites that have potential clinical benefits such as antitumor compounds such as anthracyclines (aclarubicin, daunomycin and doxorubicin), antimetabolites (pentostatin), aureolic acids (mithramycin), peptides (bleomycin and actinomycin D), enediynes (neocarzinostatin) and others [68], [69]. Marine actinomycetes developed exceptional physiological and metabolic properties that made them to survive in various habitats, and the potential to produce various compounds with therapeutic importance that are not much observed in their terrestrial members [70], [71]. Such properties could be attributed to their associations with various marine life [72]-[74]. Many type I polyketide compounds that show antitumor activity were isolated from actinomycetes of marine origin. *Salinispora arenicola* strain CNR-005 shown to produce arenicolides, a polyunsaturated macrolactone. The compound 'arenicolide A' showed cytotoxicity towards human colon adenocarcinoma cell line HCT-116 [75]. Two bicyclic polyketides, saliniketal A and B were isolated from the earlier strain. These compounds were shown to inhibit ornithine decarboxylase induction [76], [77]. *Vibrio* spp. isolate that was isolated from marine sediments was shown to produce antileukemic agent (L-asparaginase) [67]. A marine actinomycete *Micromonospora* sp. L-25-ES25-008, isolated from sponge was reported to produce a macrolide 'IB-96212' [78]. This isolated compound showed high cytotoxicity against P-388 cell line in comparison with A-549, HT-29 and MEL28 cell lines [78].

C. Beneficial Effects

Actinomycetes are known to play a role in mineralization of nutrients and organic matter decomposition, they are known to be lignocellulose decomposers [79]. They also acts as biocontrol agents, especially on cellulose containing organisms such as *Phytophthora* [80]. In agroindustry, members of this group are being explored for its metabolites, as a plant growth promoters and as well as a biocontrol agents [81], [82]. Secondary metabolites from the actinomycetes have been shown to inhibit plant pathogens. Soil actinomycete was able to inhibit *Erwinia amylovora* and *Agrobacterium tumefaciens* [102]. Members of *Streptomyces* species was shown to inhibit Oomycete members *Pythium* and *Rhizoctonia* [83]. *Streptomyces* was reported to be antagonistic to various plant pathogens such as *Alternaria*, *Botrytis*, *Fusarium*, *Pythium*, *Phomopsis*, *Rhizoctonia* and *Sclerotinia* [84]-[87]. Actinobacteria are known to play a role in humus formation and degradation of complex substances such as keratin, lignocelluloses, starch and chitin [13], [88], [89]. Xylanases were shown to be produced by *Streptomyces* spp., these enzymes are used to improve the rice straw pulp bleachability [90]. Various enzymes that are known in organic matter degradation are produced by these organisms. Enzymes such as peptidases, pectinases, hemicellulases, keratinases, chitinases (e.g. *Streptomyces viridificans*), cellulases (e.g. *Thermomonospora* spp.), proteases (*Nocardia* spp.), xylanases (*Microbispora* spp.), ligninases (*Nocardia autotrophica*), amylases (*Thermomonospora curvata*) and sugar isomerases (*Actinoplanes missouriensis*) are among the many enzymes that are produced by them [91]. Pectinases that are used widely in the clarification of fruit juices, degumming of fibres, wine making and retting of bast fibres are also reported in *Streptomyces* spp [92].

Not only for plants but also for human applications they produce enzymes. Members of actinomycetes group (*Streptomyces griseus*, *S. karnatakensis*, *S. albidoflavus* and *Nocardia* spp) were shown to be producers of L-Asparaginase [93]-[95]. L-Asparaginase is used in cancer therapy, especially in acute lymphoblastic leukemia [96], [97]. Many compounds that are having antitumor activity are also being produced from these organisms [68], [69].

They are shown to produce melanin or melanoid pigments, these pigments are also being used as a criterion in taxonomic studies [98]. Studies have shown that these pigments have radio protective and antioxidant properties [98] [99]. Melanin substances are being used in various preparations in medicine and cosmetic industry, it is being used as a bioplastic and biopolymer due to its ability to undergo polymerization [100].

D. Harmful Effects

Some of the members of actinomycetes are known to be pathogenic in nature in both plants and humans. Scab disease of potato is known to be caused by *Streptomyces scabies*. It is known to attack various underground vegetables. It produces phytotoxin named as thaxtomin that causes necrotic lesions in potato [101]. Nearly half of the actinomycetes species described so far are known to be pathogenic in nature to humans [102]. Many actinomycetes members have been isolated from less specific inflammatory conditions [103]-[109]. Some of the actinomycetes that are known to cause human diseases are *A. naeslundii*, *A. odontolyticus*, *A. viscosus*, *A. meyeri*, *A. gerencseriae* and *A. israelii* (facultatively anaerobic) [110]-[114]. Not only to humans but also to cattle these causes diseases. *Actinomycetes bovis* was shown to cause granulomatous infections in cattle [112], [114], [115]. Over all, in less than 2% of the clinical cases reported they were also known to be pathogenic in nature, especially to humans [116].

II. CONCLUSION

Diseases are the key contributors of economic losses in plant production and human health. Some of the drugs that are in current use have become ineffective against various pathogens. It is pivotal for us to identify novel sources and drugs to counter these new threats that are arising probably due to the changing climatic conditions. Actinomycetes gave us significant amount of antibiotics. But studies focusing on this group are limited in spite of their wide occurrence and distribution in various environments. Studies indicated that there is an untapped potential in this group especially from the marine sources. For isolating of novel such compounds, use of high throughput systems and advanced molecular studies might reveal better about the molecular basis of their production. Such studies should be collaborative in between the academia and industry to optimise the benefits and also multi-disciplinary involving pharmacologists, microbiologists and pathologists.

III. ACKNOWLEDGMENT

We would like to acknowledge Uka Tarsadia University for their support.

REFERENCES

- [1] S. Das, P.S Lyla, S. A Khan, "Distribution and generic composition of culturable marine actinomycetes from the sediments of Indian continental slope of Bay of Bengal", *Chin J Oceanol Limnol.*, vol.26, pp. 166-77, 2008
- [2] B. Pandey, P. Ghimire and V.P Agrawal, "Studies on the antimicrobial activity of actinomycetes isolated from Khumbu region of Nepal, PhD dissertation, Tribhuvan University, Kathmandu, Nepal", 2004.
- [3] J. Berdy, "Bioactive microbial metabolites", *Journal of Antibiotics (Tokyo)*, vol.58, pp. 1-26, 2005.
- [4] K.S Lam, "Discovery of novel metabolites from marine actinomycetes", *Current Opinion in Microbiology* vol 9, pp. 245-25, 2006.
- [5] O. Sprusansky, K. Stirrett, D. Skinner, C. Denoya and J. Westpheling, "The bkdR gene of *Streptomyces coelicolor* is required for morphogenesis and antibiotic production and encodes a transcriptional regulator of a branched-chain amino acid dehydrogenase complex", *J Bacteriol*, vol. 187, pp. 664-71, 2005
- [6] K. Wilkins, "Volatile metabolites from actinomycetes", *Chemosphere*, vol. 32, pp. 1427-1434, 1996.
- [7] T. F. Nisbet and S. P. Fox, "Alkaline protease production by an actinomycete MA1-1 isolated from marine sediments", *Ann Microbiol*, vol. 5, pp. 336-345, 1991.
- [8] G. Manuselis and C. R Mahon. "In: Textbook of diagnostic microbiology". In: C.R Manon , D.C Lehman , G Mauselis , Editors, Saunders, pp. 3-13, 2007.
- [9] M. Goodfellow, F. M Stainsby, R. Davenport, J. Chun, T. Curtis, "Activated sludge foaming: the true extent of actinomycete diversity", *Water Sci Technol*, pp. 37-511, 1998
- [10] R. J. Davenport, T. P. Curtis, M. Goodfellow, F. M Stainsby and M. Bingley, "Quatitative use of fluorescent insitu hybridization to examine relationships between mycolic acid-containing actinomycetes and foaming in activated sludge plants", *Appl Environ Microbiol*", vol 66, pp. 1158-66, 2000.
- [11] C. S. Cummins, H. Harris, "A comparison of cell-wall composition in *Nocardia*, *Actinomycetes*, *Mycobacterium* and *Propionibacterium*", *J Gen Microbiol*, vol. 15, 1956.
- [12] M. P. Lechevalier and H. Lechevalier, "Chemical composition as a criterion in the classification of Aerobic Actinomycetes", *Int J Syst Bacteriol*, vol-20, pp. 435-43, 1970
- [13] A. J. McCarthy and S. T. Williams, "Actinomycetes as agents of biodegradation in the environment-a review" *Gene*, vol. 115, pp. 189-192, 1992.
- [14] H. Schrempf, "Recognition and degradation of chitin by *Streptomyces*", *Antonie van Leeuwenhoek*, vol. 79, pp. 285-289, 2001.
- [15] R. Solanki, M. Khanna, R. Lala, "Bioactive compounds from marine actinomycetes, *Indian Journal of actinomycetes*", vol. 48: pp. 410-431, 2008.
- [16] A. T. Bull, "Microbial diversity and biospecting", *ASM Press* 2004
- [17] J. Bérdy, "Bioactive microbial metabolites: A personal view", *J Antibiot (Tokyo)*" vol 58, pp. 1-26, 2005
- [18] J. Mann, "Natural products as immunosuppressive agents", *Nat Prod Rep*, vol-18, pp. 417-430, 2001.
- [19] W. Peczniska-Czoch and M. Mordaski, "Actinomycetes in biotechnology", *Academic Press London*, pp. 219-283, 1988
- [20] T. J. Franklin, G. A. Snow, K. J. Barrett-Bee, and R. D. Nolan, "Antifungal, antiprotozoal and antiviral agents, Pages 137161 in T. J. Franklin and G.A. Snow (eds.), " *Biochemistry of antimicrobial action*", 4th ed. Chapman & Hall, New York", 1989.
- [21] H. A. Lechevalier and S. A. Waksman, "The actinomycetes. III. Antibiotics of actinomycetes" *Williams & Wilkins, Baltimore*", vol. 430, 1962.
- [22] J. Bérdy, "Bioactive microbial metabolites", *J. Antibiot*, vol. 58, pp. 1-26, 2005.
- [23] D. A. Hopwood, "Streptomyces in Nature and Medicine: The Antibiotic Makers", *New York, NY: Oxford University Press* , 2007

- [24] G. P. vanWezel, N. L. McKenzie, and J. R. Nodwell, Chapter 5. "Applying the genetics of secondary metabolism in model actinomycetes to the discovery of new antibiotics", *Methods Enzymol.* 458, 117–141, 2009
- [25] A. Prakash, F. Rigelhof and E. Miller, "Medallion Laboratories Analytical Progress, Antioxidant Activity, vol. 19(2), pp. 1-6, 2001.
- [26] G. Cassinelli, G. Rivola, D. Ruggieri, F. Arcamone, A. Grein, S. Merli, C. Spalla, A. M. Casazza, A. Di. Marco and G. Pratesi, "New anthracycline glycosides: 4-O-demethyl-11-deoxydoxorubicin and analogues from *Streptomyces peucetius* var. *aureus*." *Jpn J Antibiotics*, vol. 35(2), pp. 176-83, 1982.
- [27] H. Takano, D. Asker, T. Beppu and K. Ueda, "Genetic control for light-induced carotenoid production in nonphototrophic bacteria", *J Ind Microbiol Biotechnol*, vol. 33, pp 88-93, 2006.
- [28] H. J. Conn and J. E. Conn, "Value of pigmentation in classifying Actinomycetes", *J Bacteriol*, vol. 42(6), pp. 786-791, 1943
- [29] N. N. Gerber and B. Wieclawek. "The structures of two naphthoquinone pigments from an actinomycete." *J Org Chem*, vol. 31(5), pp. 1496-1498, 1966
- [30] C. K. Venil and P. Lakshmanaperumalsamy. "An insightful overview on microbial pigment, Prodigiosin, *Electron J Biol*, vol. 5(3), pp .49-61, 2009.
- [31] A. W. Smith, A. Camara-Artigas, C. Olea, W.A (Jr). Francisco and J. P. Allen, "Crystallization and initial X-ray analysis of phenoxazinone synthase from *Streptomyces antibioticus*". *Acta Crystallographica, Section D: Biological Crystallography*, vol. 60(8), pp. 1453-1455, 2004.
- [32] G. Z. Justo, V. Carmen, P. Ferreira, S. Melo, L. Cordi, and D. Martins, "Violacein: properties and biological activities", *Biotechnol Appl Biochem*, vol. 48, pp. 127– 133, 2007.
- [33] L. Selvameenal, M. Radhakrishnan, and R. Balagurunathan, "Antibiotic pigment from desert soil actinomycetes; biological activity, purification and chemical screening", *Indian J Pharm Sci.* 71(5): 499–504, 2009.
- [34] Z. H. Khairalla, M. A. Hewedy, H. R. Mohammed and O. M. Darwesh, "Isolation of pigment producing actinomycetes from rhizosphere soil and application it in textiles dyeing" *Research Journal of Pharmaceutical, Biological and Chemical Sciences*, 7, pp. 2128-2136, 2016
- [35] A. Asnani, D. Ryandini and Suwandri, "Screening of Marine Actinomycetes from Segara Anakan for Natural Pigment and Hydrolytic Activities" *Conf. Ser.: Mater. Sci. Eng*, 2016
- [36] R. H. Baltz, "Renaissance in antibacterial discovery from actinomycetes, *Curr. Opin Pharmacol*, vol. 8, pp. 557–63, 2008.
- [37] M. Goodfellow and A. G. O'Donnell. "Search and discovery of industrially significant Actinomycetes." In: Baumberg S, Hunter IS, Rhodes PM, editors. *Microbial Products: "New Approaches, Society for General Microbiology Symposium No. 44. Cambridge"* Cambridge University Press; pp. 343–83, 1989.
- [38] E. Kuster, "Taxonomy of soil actinomycetes and related organisms ", In: S. Gray, T. Parkinsoz, Editors, " *Ecology of soil bacteria. Liverpool, Liverpool University Press*, 1968.
- [39] D. Walker and R. R. Colwell, "Factors affecting enumeration and isolation of actinomycetes from Chesapeake Bay and South eastern Atlantic Ocean sediments" *Mar Biol*, vol. 30, pp. 193-201, 1975.
- [40] J. A. Colquhoun, J. Mexson, M. Goodfellow, A. C. Ward, K. Horikoshi and A. T. Bull, "Novel Rhodococci and other mycolate actinomycetes from the deep sea" *Antonie van Leeuwenhoek*, vol. 74, pp. 27-40, 1998.
- [41] H. Takami, A. Inoue, F. Fuji and K. Horikoshi. "Microbial flora in the deepest sea mud of the Mariana Trench" *FEMS Microbiol Lett*, vol. 152, pp. 279-85, 1997.
- [42] W. Pathom-aree, J. E. Stach, A. C. Ward, K. Horikoshi, A. T. Bull and M. Goodfellow, "Diversity of actinomycetes isolated from Challenger deep sediment (10,898 m) from the Mariana Trench", *Extremophiles*, vol. 10, pp. 181-9, 2006.
- [43] A. Raja, P. Prabhakaran, P. Gajalakshmi and A. H. Rahman, "A Population study of psychrophilic actinomycetes isolated from Rothang Hill-Manali soil sample", *J Pure Applied Microbiol*, vol. 4, pp. 847-51, 2010
- [44] P. Moncheva, S. Tishkov, N. Dimitrova, V. Chipeva and N. Bogatzevska, "Characteristics of soil actinomycetes from Antarctica", *J Cult Coll*, vol. 3, pp. 3-14, 2002
- [45] S. Deepa, K. Kanimozhi and Panneerselvam, "A.16S rDNA Phylogenetic analysis of actinomycetes isolated from marine environment associated with antimicrobial activities" *Journal for Drugs and Medicines*, vol. 5, pp. 43-50, 2014.
- [46] B. V Gopinath, P. K Vootla, R. Jyothi and S. K. Reddy, "Antimicrobial activity of actinomycetes isolated from coal mine soils of Godavari belt region, A.P, India", *Asian Journal of Experimental Biological Sciences*, vol. 4, pp. 518-523, 2013.
- [47] L. S. Jeffrey "Isolation, characterization and identification of actinomycetes from agriculture soils at Semongok, Sarawak", *Afr. J. Biotechnol*, vol. 7, pp. 3697-3702, 2008.
- [48] M. Arifuzzaman, M. R. Khatun and H. Rahman, "Isolation and screening of actinomycetes from Sundarbans soil for antibacterial activity", *Afr. J. Biotechnol*, vol. 9, pp. 4615 – 4619, 2010.
- [49] H. J. Kim, S. C. Lee and B. K. Hwang, "Streptomyces cheonanensis sp. nov., a novel streptomycete with antifungal activity", *Int J Syst Evol Microbiol*, vol. 56, pp. 471–475, 2006.
- [50] M. G. Watve, R. Tickoo, M. M. Jog, B. D. Bhole, "How many antibiotics are produced by the genus Streptomyces", *Arch Microbiol*, vol. 176, pp. 386-390, 2001.
- [51] S. N. Debananda, S. Sanasam and N. Salam, "Screening of actinomycete isolates from niche habitats in Manipur for antibiotic activity", *Am J Biochem Biotech*, vol. 5(4), pp. 221-225, 2009
- [52] S. Z. Qasim, "The Indian Ocean: images and realities Oxford and IBH, New Delhi", pp. 57–90, 1999.
- [53] A. T. Bull, A. C. Ward and M. Goodfellow, "Search and discovery strategies for biotechnology: the paradigm shift, microbial", *Mol Biol Rev*, vol. 64, pp. 573-606, 2000
- [54] K. S. Lam, "Discovery of novel metabolites from marine actinomycetes", *Curr. Opin Microbiol*, vol. 9, pp. 245–251, 2006
- [55] W. Fenical and P. R. Jensen, "Developing a new resource for drug discovery: marine actinomycete bacteria", *Nat Chem Biol*, vol. 2, pp. 666–673, 2006.
- [56] E. Helmke and H. Weyland, "Rhodococcus marinonascens sp. nov., an Actinomycete from the Sea", *Int. J. Syst. Bacteriol*, vol. 34, pp.127–138, 1984.
- [57] M. A. Moran, L. T. Rutherford and R. E. Hodson, "Evidence for indigenous Streptomyces populations in a marine environment determined with a 16S rRNA probe", *Appl. Environ. Microbiol*, vol. 61, pp. 3695–3700, 1995.
- [58] P. R. Jensen, R. Dwight and W. Fenical, "Distribution of actinomycetes in near-shore tropical marine sediments", *Appl. Environ. Microbiol*, vol. 57, pp. 1102–1108, 1991

- [59] S. Dharmaraj, "Marine Streptomyces as a novel source of bioactive substances", *World J Microbiol, Biotechnol.*, vol. 26, pp. 2123–2139, 2010
- [60] S. Dharmaraj, "Marine Streptomyces as a novel source of bioactive substances", *World J Microbiol, Biotechnol.*, vol. 26, pp. 2123–2139, 2010.
- [61] T. J. Mincer, P. R. Jensen, C. A. Kauffman and W. Fenical, "Widespread and persistent populations of a major new marine actinomycete taxon in ocean sediments", *Appl. Environ. Microbiol.*, vol. 68, pp. 5005–5011, 2002.
- [62] L. A. Maldonado, W. Fenical, P. R. Jensen, C. A. Kauffman, T. J. Mincer, A. C. Ward, A. T. Bull and M. Goodfellow, "Salinispora arenicola gen. nov., sp. nov. and Salinispora tropica sp. nov., obligate marine actinomycetes belonging to the family Micromonosporaceae", *Int. J. Syst. Evol. Microbiol.*, vol. 55, pp. 1759–1766, 2005.
- [63] J. Riegdlinger, A. Reicke, H. Zahner, B. Krismer, A. T. Bull, L. A. Maldonado, A. C. Ward, M. Goodfellow, B. Bister and D. Bischoff, "Abyssomicins, inhibitors of the para-aminobenzoic acid pathway produced by the marine Verrucospora strain AB-18-032", *J. Antibiot.*, vol. 57, pp. 271–277, 2004.
- [64] R. D. Charan, G. Schlingmann, J. Janso, V. Bernan, X. Feng, G. T. Carter, "Diazepinomicin, a new antimicrobial alkaloid from marine Micromonospora sp." *J. Nat. Prod.*, vol. 67, pp. 1431–1433, 2004
- [65] M. K. Renner, Y. C. Shen, X. C. Cheng, P. R. Jensen, W. Frankmoelle, C. A. Kauffman, W. Fenical, E. Lobkovsky and J. Clardy, "Cyclomarins AC, new anti-inflammatory cyclic peptides produced by a marine bacterium (Streptomyces sp.)", *Journal of the American Chemical Society*, vol. 121, pp. 11273–11276, 1999
- [66] V. R. Dasari, M. K. Muthyala, M. Y. Nikku and S. R. Donthireddy, "Novel Pyridinium compound from marine actinomycete, Amycolatopsis alba var. nov. DVR D4 showing antimicrobial and cytotoxic activities in vitro", *Microbiological Research*, vol. 167, 2012.
- [67] I. E. Soria-Mercado, A. Prieto-Davo, P. R. Jensen and W. Fenical, "Antibiotic terpenoid chlorodihydroquinones from a new marine actinomycete", *Journal of Natural Products*, vol. 68, pp. 904–910, 346–351, 2005
- [68] D. Chandramohan, "Recent advances in marine microbiology, The Indian scenario", *J. Mar. Biotechnol.*, vol. 5, pp. 73–81, 1997
- [69] D. J. Newman, G. M. Cragg, "Natural products as sources of new drugs over the last 25 years", *J. Nat. Prod.*, vol. 70, pp. 461–477, 2007.
- [70] C. Olano, C. Méndez and J. A. Salas, "Antitumor compounds from actinomycetes: from gene clusters to new derivatives by combinatorial biosynthesis", *Nat. Prod. Rep.*, vol. 26, pp. 628–660, 2009
- [71] J. W. Blunt, B. R. Copp, M. H. Munro, P. T. Northcote, M. R. Prinsep, "Marine natural products", *Nat. Prod. Rep.*, vol. 23, pp. 26–78, 2006.
- [72] W. Fenical, K. M. Sethna, G. K. Lloyd, "Marine microorganisms as a developing resource for drug discovery", *Pharm. News*, vol. 9, pp. 489–494, 2002
- [73] R. H. Baltz, "Renaissance in antibacterial discovery from actinomycetes", *Curr. Opin. Pharmacol.*, vol. 8, pp. 557–563, 2008.
- [74] J. Piel, "Metabolites from symbiotic bacteria", *Nat. Prod. Rep.*, vol. 21, pp. 519–538, 2004.
- [75] R. Gandhimathi, M. Arunkumar, J. Selvin, T. Thangavelu, S. Sivaramakrishnan, G. S. Kiran, S. Shanmughapriya and K. Natarajaseenivasan, "Antimicrobial bioactive metabolites", *Applied and Environmental Microbiology*, vol. 70, pp. 7520–7529, 2008
- [76] P. G. Williams, E. D. Miller, R. N. Asolkar, P. R. Jensen, W. Fenical and A. C. Arenicolidis, "26 membered ring macrolides from the marine actinomycete Salinispora arenicola." *J. Org. Chem.*, pp. 5025–5034, 2007.
- [77] P. G. Williams, R. N. Asolkar, T. Kondratyuk, J. M. Pezzuto, P. R. Jensen, W. Fenical, "Saliniketals A and B, bicyclic polyketides from the marine actinomycete Salinispora arenicola", *J. Nat. Prod.*, vol. 70, pp. 83–88, 200
- [78] E. W. Gerner and F. L. Meyskens, "Jr. Polyamines and cancer: old molecules, new understanding", *Nat. Rev. Cancer*, vol. 4, pp. 781–792, 2004.
- [79] R. I. Fernández-Chimeno, L. Cañedo, F. Espliego, D. Grávalos, F. De La Calle, J. L. Fernández Puentes, F. Romero, "IB-96212, a novel cytotoxic macrolide produced by a marine Micromonospora. I. Taxonomy, fermentation, isolation and biological activities", *J. Antibiot.*, vol. 53, pp. 474–478, 2000.
- [80] K. Chamberlain and D. L. Crawford, "Thatch biodegradation and antifungal activities of two lignocellulolytic Streptomyces strains in laboratory cultures and in golf green turfgrass", *Can. J. Microbiol.*, vol. 46, pp. 550–558, 2000.
- [81] L. H. C. Lima, J. L. De Marco and C. R. Felix, "Enzimas hidrolíticas envolvidas no controle por micoparasitismo", In: MELO, I.S.; AZEVEDO, J.L. (Ed.), "Controle biológico. Jaguariúna: Embrapa- CNPMA", pp. 263–304, 1998.
- [82] V. Behal, "Bioactive products from Streptomyces", *Adv. Appl. Microbiol.*, vol. 47, pp. 113–157, 2000.
- [83] Y. Tanaka and S. Omura, "Agroactive compounds of microbial origin", *Annu. Rev. Microbiol.*, vol. 47, pp. 57–87, 1993.
- [84] W. M. Yuan, D. Crawford, "Characterization of Streptomyces lydicus WYE108 as potential biocontrol agent against fungal root and seed rots", *Appl. Environ. Microbiol.*, vol. 61, pp. 3119–3128, 1995
- [85] R. Tahvonen, "The suppressiveness of Finnish light coloured Sphagnum peat", *J. Agric. Sci. Finl.*, vol. 54, pp. 345–356, 1982.
- [86] R. Tahvonen, "Preliminary experiments into the use of Streptomyces spp. isolated from peat in the biological control of soil and seedborne disease in peat culture", *J. Agric. Sci. Finl.*, vol. 54, pp. 357–369, 1982.
- [87] R. Tahvonen and H. Avikainen, "The biological control of seedborne Alternaria brassicicola of cruciferous plants with a powdery preparation of Streptomyces sp.", *J. Agric. Sci. Finl.*, vol. 59, pp. 199–208, 1987.
- [88] O. Mohammadi and M. L. Lahdenpera, "Mycostop biofungicide in practice. Pages 1–7 in 10th International symposium on modern fungicides and antifungal compounds", Thuringia, Germany, 1992.
- [89] M. Goodfellow, S. T. Williams, "Ecology of actinomycetes", *Annu. Rev. Microbiol.*, vol. 37, pp. 189–216, 1983
- [90] J. E. Stach and A. T. Bull, "Estimating and comparing the diversity of marine actinobacteria", *Antonie van Leeuwenhoek*, vol. 87, pp. 3–9, 2005
- [91] H. M. Rifaat, Z. A. Nagieb and Y. M. Ahmed, "Production of xylanases by Streptomyces species and their bleaching effect on rice straw pulp," *Applied Ecology and Environmental Research*, vol. 4, no.1, pp. 151–160, 2006.
- [92] M. Solans and G. Vobis, "Saprophytic actinomycetes associated to the rhizosphere and rhizoplane of Discaria trinervis", *Ecologia Australiana*, vol. 13, pp. 97–107, 2003.
- [93] N. Jacob, C. Asha Poorna and P. Prema, "Purification and partial characterization of polygalacturonase from Streptomyces lydicus," *Bioresource Technology*, vol. 99, no.14, pp. 6697–6701, 2008.
- [94] P. J. DeJong, "L-Asparaginase production by actinomycete antagonistic to Phytophthora spp." *Appl. Microbiol. Biotechnol.*, vol. 57, pp. 117–123, 1972
- [95] Narayana K. J. P. et al, "L-asparaginase production by Streptomyces albidoflavus", *Indian J. Microbiol.*, vol. 48(3), pp. 331–336, 2007
- [96] S. A. Mostafa and M. S. Salama, "L-asparaginase producing Streptomyces from soil of Kuwait", *Zentralbl. Bakteriol. Naturwiss.*, vol. 134(4), pp. 325–334, 1979.

- [97] M. P. Gallagher, et al., "Asparaginase drug for treatment of acute lymphoblastic leukemia", *Essays Biochem.*, vol. 24, pp.1-40, 1989
- [98] N. Verma, et al., "L-asparaginase: a promising chemotherapeutic agent", *Crit. Rev. Biotechnol.*, vol. 27(1), pp. 45-62, 2007.
- [99] S. G. Li, W. J. Dastager, A. Dayanand, S. K. Tang, X. P. Tian, X. Y. Xu, L. HZhi, and C. L. Jiang, "Separation, identification and analysis of pigment (melanin) production in *Streptomyces*", *African J. of Biotechnology*, vol. 5, pp. 1131-1134, 2006.
- [100] S. Frases, A. Salazar, E. Dadachova, and A. Casadevall, "Cryptococcus of applied and can utilize the bacterial melanin precursor homogentisic acid for fungal melanogenesis", *J. Environ. Microbiol.*, vol. 73(2), pp. 615-621, 2007.
- [101] L. Nakato, "Melanin and Bio/Nanotechnology", Blackherbals at the Source of the Nile, UG Ltd, 2006
- [102] J. L. Schottel, K. Shimizu and L. L. Kinkel, "Relationships of in vitro pathogen inhibition and soil colonization to potato scab biocontrol by antagonistic *Streptomyces* spp.", *Biol Control*, vol. 20, pp. 102-112, 2001.
- [103] F. Valour, A. Sénéchal, C. Dupieux, J. Karsenty, S. Lustig, P. Breton, A. Gleizal, L. Bousset, F. Laurent, E. Braun, C. Chidiac, F. Ader and T. Ferry, "Actinomycosis: etiology, clinical features, diagnosis, treatment, and management", *Infection and Drug Resistance*, vol. 7, pp. 183-197, 2014.
- [104] M. D. Collins, L. Hoyle, S. Kalfas, G. Sundquist, T. Monsen, N. Nikolaitchouk, E. Falsen, "Characterization of *Actinomyces* isolates from infected root canals of teeth: Description of *Actinobacillus radicidentis* sp. nov.", *J Clin Microbiol.*, vol 38, pp. 3399-3403, 2000.
- [105] G. Funke, N. Alvarez, C. Pascual, E. Falsen, E. Åkervall, L. Sabbe, L. Schouls, N. Weiss and M. D. Collins, "*Actinobacillus europaeus* sp. nov., isolated from human clinical specimens", *Int J Syst Bacteriol*, vol. 47, pp. 687-692, 1997.
- [106] P. A. Lawson, N. Nikolaitchouk, E. Falsen, K. Westling and M. D. Collins, "*Actinomyces funkei* sp. nov., isolated from human clinical specimens", *Int J Syst Evol Microbiol.*, vol 51, pp. 853-855, 2001.
- [107] C. P. Ramos, E. Falsen, N. Alvarez, E. Åkervall, B. Sjöden and M. D. Collins, "*Actinomyces graevenitzii* sp. nov., isolated from human clinical specimens", *Int J Syst Bacteriol.*, vol. 47 pp. 885-888, 1997.
- [108] J. Wüst, S. Stubbs, N. Weiss, G. Funke and M. D. Collins, "Assignment of *Actinomyces pyogenes*-like (CDC coryneform group E) bacteria to the genus *Actinomyces* as *Actinomyces radingae* sp. nov. and *Actinomyces turicensis* sp. nov.", *Lett Appl Microbiol.*, vol. 20, pp. 76-112, 1995.
- [109] P. A. Lawson, E. Falsen, E. Åkervall, P. Vandamme and M. D. Collins, "Characterization of some *Actinomyces*-like isolates from human clinical specimens: Reclassification of *Actinomyces suis* (Soltys and Spratling) as *Actinobaculum suis* comb. nov. and description of *Actinobaculum schaalii* sp. nov.", *Int J Syst Bacteriol*, vol. 47, pp. 899-903, 1997.
- [110] S. Lam, J. Samraj, S. Rahman, "Hilton E. Primary actinomycotic endocarditis: case report and review", *Clin Infect Dis.*, vol. 16, pp.481-485, 1993.
- [111] B. K. Adams and J. H. Crosier, "Bone and gallium scintigraphy in polyostotic actinomycosis of the upper limb", *Clin Nucl Med.*, vol. 19, pp. 254-256, 1994.
- [112] J. Atad, M. Hallak, A. Sharon, R. Kitzes, Y. Kelner, "Abramovici H. Pelvic actinomycosis: is long-term antibiotic therapy necessary", *J Reprod Med.*, vol. 44, pp. 939-944, 1999.
- [113] D. F. Bennhoff, "Actinomycosis: diagnostic and therapeutic considerations and a review of 32 cases", *Laryngoscope*, vol. 94, pp. 1198-1217, 1984.
- [114] H. D. Birley, E. L. Teare and J. A. Utting, "Actinomycotic osteomyelitis of the thoracic spine in a penicillin-sensitive patient [Letter]", *J Infection*, vol. 19, pp. 193-194, 1989.
- [115] A. Boand and M. Novak, "Sensitivity changes of *Actinobacillus bovis* to penicillin and streptomycin", *J Bacteriol*, 57, 501-508, 1949
- [116] F. Lentze, "Die Aktinomykose und die Nocardiosen. In: Grumbach A, Bonin O, eds. *Die Infektionskrankheiten des Menschen und ihre Erreger*", vol I, 2nd ed. Stuttgart: Georg Thieme", pp. 83-92, 1969
- [117] R. A. Smego, Jr and G. Foglia, "Actinomycosis" *Clin Infect Dis*, vol. 26, pp.1255-1263, 1998.

10.22214/IJRASET

45.98

IMPACT FACTOR:
7.129

IMPACT FACTOR:
7.429

INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY

Call : 08813907089 (24*7 Support on Whatsapp)